Market Context — Why This Technology, Why Now

The global regenerative medicine market is experiencing exponential growth, fueled by breakthroughs in cell therapy and tissue engineering. However, manufacturing scalability, cell viability, and product consistency remain major hurdles. Stricter regulatory demands for product quality and efficacy necessitate innovative solutions for cell handling and integration. This technology offers a robust platform to meet these challenges, enabling faster development cycles and higher-quality therapeutic products.

Key Competitive Advantages
01

Minimizes physical stress on cells during vacuum-pressure processing, potentially improving post-introduction cell viability and function retention by 15%.

02

Ensures efficient dispersion liquid penetration into porous materials via vacuum and uniform filling via pressure, contributing to stable product quality.

03

Applicable regardless of porous material or solid type, enabling diverse applications in regenerative medicine product development.

Market Opportunity
Regenerative Medicine Product Development
$6.5B–$7B globally (AI est.)
This technology is essential for improving cell introduction quality and efficiency in the development and manufacturing of diverse regenerative medicine products, including cell sheets, tissue-engineered products, and cell transplantation therapies.
Cell therapy developers Tissue engineering companies Contract manufacturing organizations (CMOs) for biologics
Drug Discovery Screening
$2B globally (AI est.)
Efficiently introducing drugs into 3D cell culture models and organoids enables more physiologically relevant drug efficacy evaluations, contributing to higher success rates in new drug development.
Pharmaceutical R&D divisions Biotech companies specializing in 3D culture CROs offering drug screening services
Biomaterial Manufacturing
$1.5B globally (AI est.)
Introducing cells and biomolecules into functional biomaterials facilitates the development of novel medical devices, diagnostic agents, and research tools.
Medical device manufacturers Diagnostic kit developers Research tool and reagent suppliers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a method for introducing solids into porous materials, with claims that were successfully defended against extensive prior art. The robust prosecution history, including effective amendments and arguments, indicates a strong, stable right less susceptible to invalidation by competitors.

Competitive White Space

This patent primarily covers the method of introducing solids into porous materials. White space could include novel porous material compositions themselves, advanced post-introduction processing for maturation, or specific device designs that leverage this method for unique applications beyond general regenerative medicine.

Economic Impact
~$1M/year estimated cost savings per facility (est.).
estimated ROI · USD · AI analysis
ROI Calculation Logic

For a company with ~$3.5M (AI est.) in annual R&D, shortening development time by 20% could save ~$0.5M (AI est.), and reducing material loss by 10% could save an additional ~$0.5M (AI est.), totaling an estimated ~$1M (AI est.) in annual economic impact.

Speed to Market
4× faster than in-house development
This technology's fundamental concept has been established through basic research by Shinshu University. It applies general physical processes like vacuum and pressure, making it relatively easy to integrate into existing manufacturing facilities. Its versatility, validated across various cell and material types, is estimated to significantly shorten time-to-market compared to new in-house development.
Competitive Positioning

X: Cell Function Retention
Y: High-Density, Uniform Introduction Efficiency

Business Models & Applications
🤝 Technology Licensing
A model to generate revenue by granting technology usage rights through licensing agreements to regenerative medicine companies, pharmaceutical firms, and research institutions requiring this technology.
🔬 Joint Research & Development
A model to collaborate with licensees on R&D for specific regenerative medicine products or biomaterials, earning revenue sharing or royalties based on outcomes.
🏭 Contract Manufacturing Services
A service model to provide high-quality porous materials or tissue constructs with introduced cells to regenerative medicine product manufacturers and research institutions using this technology.
Adjacent Application Opportunities
🧪 Pharmaceutical Development
Drug Delivery System (DDS) Carrier Manufacturing
Efficiently and stably introduces drugs or genes into porous carriers, enabling the development of high-precision targeted delivery systems. This could lead to reduced side effects and maximized drug efficacy.
🥩 Food & Bio-Production
Cultured Meat & Fish Tissue Formation
High-density, uniform introduction of animal cells into porous scaffold materials could establish manufacturing technology for cultured meat and fish with more complex, realistic tissue structures, potentially contributing to food security solutions.
♻️ Environment & Energy
High-Performance Catalyst & Adsorbent Development
Efficiently introduces specific catalyst particles or adsorbents into porous materials, enabling the development of high-performance materials for environmental purification, CO2 separation, and energy conversion, contributing to a sustainable society.
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Proof of Concept & Technical Evaluation
Duration: 4 months
Verify the basic principles and introduction process of this technology. Small-scale demonstration experiments using the licensee's porous materials and solid samples will evaluate technical suitability and initial effects.
Phase 2: Prototype Development & Optimization
Duration: 9 months
Based on evaluation results, develop a prototype system or procedure tailored to the licensee's specific products or processes. Optimize introduction conditions and conduct performance evaluations to establish a foundation for practical application.
Phase 3: Mass Production Planning & Market Launch
Duration: 9 months
Advance planning and preparation for integrating the optimized process into manufacturing lines. Establish quality control systems, ensure regulatory compliance, and formulate and execute market launch strategies for regenerative medicine products.
Technical Feasibility
This technology combines physical processes like vacuum and pressure with general dispersion liquid injection, making it highly feasible for integration into existing cleanroom facilities and cell culture equipment. The sealed container, vacuum, and pressure devices described in the claims can be replaced with standard laboratory and manufacturing equipment, indicating high technical feasibility for adoption without significant new capital investment.
Success Scenario
Implementing this technology could improve cell yield in regenerative medicine product manufacturing by 15% over current methods, significantly enhancing product quality stability. This is estimated to shorten development cycles by up to 20%, accelerating product launch into the market.
Patent Record
APPLICATION NO.
特願2020-094285
REGISTRATION NO.
7522436
FILING DATE
2020/05/29
GRANT DATE
2024/07/17
EXPIRATION DATE
2040/05/29
PATENT HOLDER
国立大学法人信州大学
Examination History
2023年01月17日
出願審査請求書
2023年11月28日
拒絶理由通知書
2024年03月15日
手続補正書（自発・内容）
2024年03月15日
意見書
2024年06月25日
特許査定